**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:** CAN/2015-16/452

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | LAMIVUDINE, ZIDOVUDINE AND NEVIRAPINE TABLETS 150 mg/300 mg/200 mg | | REF. NO: NDQB201601693 |
| **DATE RECEIVED:** 26.01.2016 | **LABEL CLAIM:** | Each film-coated tablet contains Lamivudine USP 150 mg, Zidovudine USP 300 mg, Nevirapine USP 200 mg. | |
| **BATCH NO.:** X40412 | **PRESENTATION:** | White coloured, caplet-shaped, biconvex faced tablets, embossed 'LZN' on one face and plain on the other, packed in a white plastic multidose container carrying 60 tablets in a unit box. | |
| **MGF. DATE:** May 2014 | **MANUFACTURER:** | CIPLA Ltd. | |
| **EXP. DATE:**  Apr. 2017 | **ADDRESS:** | Verna, Goa 403 722, INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | Kenya Medical Supplies Authority, P.O. Box 47715 - 00100, Nairobi, KENYA | |
| 17 NAKURU PGH | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

**RESULTS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | BP 2016 Vol. V App XII C | NMT 2 tablets deviate by more than 5% from mean tablet weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC | Adopted In-House Method | RT of the component Peaks in the assay sample preparation correspond to those in the standard preparation | Super-imposable peaks at RT 3.2, 4.3 and 7.1-/+ 10% min present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | lamivudine 107.3% (RSD=1.1%, n=6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Dissolution** | HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | Nevirapine 105.5% (RSD=1.2%, n=6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Dissolution** | HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | Zidovudine 104.9% (RSD=1.0%, n=6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC | Adopted In-House Method | 90.0 - 110.0% | lamivudine 108.3% (RSD=1.9%, n=9) | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC | Adopted In-House Method | 90.0 - 110.0% | Nevirapine 107.6% (RSD=1.2%, n=9) | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC | Adopted In-House Method | 90.0 - 110.0% | Zidovudine 107.6% (RSD=1.1%, n=9) | **COMPLIES:COMPLIES:COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| ANALYST: | DR. E. MUTUA |  | DATE:02-12-2016 |
| ANALYST: | DR. G. WANG'ANG'A |  | DATE:03-07-2016 |
| ANALYST: | ERNEST MBAE |  | DATE:03-18-2016 |
| DIRECTOR: | HEZEKIAH CHEPKWONY |  | DATE:03-29-2016 |